- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Arbutus Biopharma Corp (ABUS)Assess today's live Arbutus Biopharma Corp (ABUS) share price, performance and insights using our live NASDAQ: ABUS stock exchange data.
Analyse the historical data and Arbutus Biopharma Corp share price performance charts on this page. Our technical summary section provides analysis on Arbutus Biopharma share price buy/sell indicators using real-time data (or discuss the Arbutus Biopharma (ABUS) stock price today with other investors in the Arbutus Biopharma NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ ABUS share price (ISIN: CA03879J1003) to enhance your trading decisions with our free investment tools and resources.
What Is the Arbutus Biopharma Corp Share Price Today?
The Arbutus Biopharma share price today is 3.488.
What Is the Stock Symbol for Arbutus Biopharma Corp
The stock symbol (or 'ticker') for Arbutus Biopharma Corp is "ABUS."
What Stock Exchange Does Arbutus Biopharma Corp Trade On?
Arbutus Biopharma Corp is listed and trades on the NASDAQ stock exchange.
Is Arbutus Biopharma Corp a Good Stock to Buy?
Determining whether Arbutus Biopharma Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Arbutus Biopharma Corp share price performance charts on this page. Our technical summary section provides analysis on Arbutus Biopharma share price buy/sell indicators using real-time data (or discuss the Arbutus Biopharma (ABUS) stock price today with other investors in the Arbutus Biopharma NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ ABUS share price (ISIN: CA03879J1003) to enhance your trading decisions with our free investment tools and resources.
What Is the Arbutus Biopharma Corp Share Price Today?
The Arbutus Biopharma share price today is 3.488.
What Is the Stock Symbol for Arbutus Biopharma Corp
The stock symbol (or 'ticker') for Arbutus Biopharma Corp is "ABUS."
What Stock Exchange Does Arbutus Biopharma Corp Trade On?
Arbutus Biopharma Corp is listed and trades on the NASDAQ stock exchange.
Is Arbutus Biopharma Corp a Good Stock to Buy?
Determining whether Arbutus Biopharma Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Currency in USD
3.488
+0.028(+0.82%)
Real-time Data
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.460
3.515
52 wk Range
1.980
4.725
ABUS Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.4603.515
52 wk Range
1.9804.725
Key Statistics
Edit
Book Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
UnlockN/A
(N/A)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockBook Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
UnlockN/A
(N/A)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockABUS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Sell
Price Target
7.284
Upside
+108.830%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings upwards for the upcoming period
Arbutus Biopharma Company Profile
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company’s research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients’ HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Arbutus Biopharma Corp SWOT Analysis
Strategic Pivot | Arbutus Biopharma refocuses on lead siRNA candidate imdusiran for chronic hepatitis B treatment, extending cash runway to Q4 2026 through restructuring |
Promising Trial Results | Explore imdusiran's efficacy in combination with interferon, showcasing potential as a cornerstone therapy for chronic hepatitis B |
Legal Victories | Delve into Arbutus' favorable rulings against Moderna in lipid nanoparticle technology patent disputes, potentially unlocking significant financial benefits |
Analyst Outlook | JMP Securities maintains Market Outperform rating with price targets ranging from $4.00 to $5.00, reflecting confidence in Arbutus' strategic direction |
ABUS Full Pro Research
Institutional-Grade Stock Analysis
Understand how ABUS earns money
Financial health at a glance
Bearish and bullish outlooks
Latest expert insights
Actionable Pro Tips, and many more...
Gain access to 1400+ in-depth research reports on the most popular US stocks
Arbutus Biopharma Corp Earnings Call Summary for Q3/2024
- Positive Phase 2a data for imdusiran in hepatitis B treatment; Phase 2b development planned
- 40% workforce reduction to streamline operations and extend cash runway through Q4 2026
- $148.5 million cash balance; sufficient to fund upcoming Phase 2b trial
- Litigation update: trial with Moderna and Pfizer/BioNTech set for April 21, 2025
- Considering focus on patients with baseline HBsAg levels below 1,000 for higher response rates
Last Updated: 01/08/2024, 21:50
Read Full TranscriptCompare ABUS to Peers and Sector
Metrics to compare | ABUS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipABUSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −8.6x | −9.5x | −0.7x | |
PEG Ratio | −1.06 | −0.17 | 0.00 | |
Price/Book | 6.2x | 2.1x | 2.6x | |
Price / LTM Sales | 97.9x | 20.8x | 3.2x | |
Upside (Analyst Target) | 45.0% | 48.2% | 44.5% | |
Fair Value Upside | Unlock | 1.5% | 6.6% | Unlock |
Analysts' Recommendations
4 Buy
1 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 5.191
(+48.83% Upside)
People Also Watch
FAQ
What Is the Arbutus Biopharma (ABUS) Stock Price Today?
The Arbutus Biopharma stock price today is 3.488
What Stock Exchange Does Arbutus Biopharma Trade On?
Arbutus Biopharma is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for Arbutus Biopharma?
The stock symbol for Arbutus Biopharma is "ABUS."
What Is the Arbutus Biopharma Market Cap?
As of today, Arbutus Biopharma market cap is 660.95M.
What is Arbutus Biopharma Earnings Per Share?
The Arbutus Biopharma EPS is -0.425.
What Is the Next Arbutus Biopharma Earnings Date?
Arbutus Biopharma will release its next earnings report on 27 Feb 2025.
From a Technical Analysis Perspective, Is ABUS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.